FIP Seminar: Optical Imaging for Personalized Cancer Therapy

Oct 18

Wednesday, October 18, 2017

12:00 pm - 1:00 pm
Fitzpatrick Center Schiciano Auditorium Side B

Presenter

Dr. Darren Roblyer, Assistant Professor, Department of Biomedical Engineering, Boston University

Despite an ever increasing set of chemotherapeutic and targeted therapies for patients suffering from cancer, individual responses and resistance patterns remain highly variable. Standard-of-care imaging modalities (MRI, PET-CT, etc.) have limited ability to detect response and resistance early and often during treatment due to access, cost, and safety concerns. In order to move towards truly adaptive chemotherapeutic regimens, near real-time in vivo measurements of key response metrics are needed. Towards this goal, there has been significant interest in chemotherapy monitoring in breast cancer patients using diffuse optical technologies. Multiple groups, including ours, have demonstrated prognostic changes in endogenous chromophores after days, weeks or months of treatment. In order to translate these early findings to the standard of care, it's necessary to 1. Validate optical signatures of treatment response and resistance in larger patient populations, 2. Screen unexplored treatment timepoints using new, more clinically versatile optical technologies, and 3. Identify causative associations between and diffuse optical measurements and specific molecular events. In order to meet these challenges, our group is developing a variety of new clinical and preclinical diffuse optical measurement platforms including a new wearable continuous-wave infusion monitor and a portable all-digital frequency-domain Diffuse Optical Spectroscopy (DOS) system to access patients at the point-o

Add to calendar

Contact

Burns, August
660-5598
august.burns@duke.edu